Search

Your search keyword '"5-HT3 receptor antagonists"' showing total 143 results

Search Constraints

Start Over You searched for: Descriptor "5-HT3 receptor antagonists" Remove constraint Descriptor: "5-HT3 receptor antagonists"
143 results on '"5-HT3 receptor antagonists"'

Search Results

1. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

2. Adjunctive granisetron therapy in patients with sepsis or septic shock (GRANTISS): A single-center, single-blinded, randomized, controlled clinical trial.

3. Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial.

4. Clinical efficacy of 5-hydroxytryptamine 3 receptor antagonists in reducing propofol injection pain, postoperative nausea/vomiting and shivering: A meta-analysis

8. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

9. Pharmacodynamics of Serotonin. Emphasis on 5HT-3 Antagonists and SSRI Medication (I).

10. Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of ‘overall’ nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.

11. 5-HT3 Receptor Antagonists for the Prevention of Perioperative Shivering: A Meta-Analysis.

12. 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.

13. Acupuncture combined with ondansetron for prevention of postoperative nausea and vomiting in high-risk patients undergoing laparoscopic gynaecological surgery: A randomised controlled trial.

14. Clinical efficacy of 5-hydroxytryptamine 3 receptor antagonists in reducing propofol injection pain, postoperative nausea/vomiting and shivering: A meta-analysis

15. 5-HT3 receptor antagonists protect against pressure overload-induced cardiac hypertrophy in murine

16. Pharmacodynamics of Serotonin. Emphasis on 5HT-3 Antagonists and SSRI Medication (I).

17. Farmacoterapia actual de náuseas y vómitos inducidos por antineoplásticos

18. Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens.

19. 5-HT3 receptor antagonists do not alter spontaneous contraction of pregnant myometrium in vitro.

20. Antidepressant-like effect of a novel 5-HT3 receptor antagonist N-(benzo[d] thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide 6k using rodents behavioral battery tests.

21. On-line focusing of 5-hydroxy-tryptamine type 3 receptor antagonists via the combination of field-enhanced sample injection and dynamic pH junction in capillary electrophoresis with amperometric detection.

22. 5-HT

23. Adjunctive granisetron therapy in patients with sepsis or septic shock (GRANTISS): A single-center, single-blinded, randomized, controlled clinical trial.

24. Antidepressant-like effect of novel 5-HT3 receptor antagonist N-n-butyl-3-ethoxyquinoxalin-2-carboxamide (6p): An approach using rodent behavioral antidepressant tests.

25. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n).

26. 5-HT3 receptor antagonists protect against pressure overload-induced cardiac hypertrophy in murine.

27. Quinoxalin-2-carboxamides: synthesis and pharmacological evaluation as serotonin type-3 (5-HT3) receptor antagonists.

28. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.

29. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.

30. Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides

31. Design, synthesis and structure–activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression

32. Efficacy of Granisetron in the Antiemetic Control of Nonsurgical Intestinal Obstruction in Advanced Cancer: A Phase II Clinical Trial

34. Efficacy of tropisetron in patients with advanced non-small-cell lung cancer receiving adjuvant chemotherapy with carboplatin and taxanes.

35. Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene.

36. Costs of Uncontrolled Chemotherapy-Induced Nausea and Vomiting Among Working-Age Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy.

37. A randomized blinded study of the incidence of postoperative nausea and vomiting in women after major gynecologic laparoscopic surgery.

38. Lack of Reciprocity between Opioid and 5-HT3 Receptors for Antinociception in Rat Spinal Cord.

39. Support vector classification for SAR of 5-HT3 receptor antagonists.

40. Blockade of 5-HT3 receptor with MDL7222 and Y25130 reduces hydrogen peroxide-induced neurotoxicity in cultured rat cortical cells

41. Role of Neurokinin-1 Receptor Antagonists in Chemotherapy-Induced Emesis: Summary of Clinical Trials.

42. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.

43. Was gibt es Neues in der Therapie der Fibromyalgie?

44. Local treatment of tendinopathies: a comparison between tropisetron and depot corticosteroids combined with local anesthetics.

45. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists - preliminary results.

46. The use of 5-HT3 receptor antagonists in various rheumatic diseases - a clue to the mechanism of action of these agents in fibromyalgia?

47. Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial.

48. 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

49. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron

50. The effect of Gly–Gln [ß-endorphin30–31] on morphine-evoked serotonin and GABA efflux in the nucleus accumbens of conscious rats

Catalog

Books, media, physical & digital resources